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Estrogen Replacement Therapy and Cognitive Functioning in the
Atherosclerosis Risk in Communities (ARIC) Study
Moyses Szklo,1 James Cerhan,2 Ana V. Diez-Roux,1 Uoyd Chambless,3 Lawton Cooper,4 Aaron R. Folsom,5
Linda P. Fried,8 David Knopman,7 and F. Javier Nieto1
The association of estrogen replacement therapy (ERT) with cognitive functioning was assessed in 6,110
women aged 48-67 years participating in the Atherosclerosis Risk in Communities (ARIC) study, a muiticenter
longitudinal investigation. ERT was evaluated in relation to results of three cognitive tests (the Delayed Word
Recall (DWR) Test, the Digit Symbol Subtest of the Wechsler Adult Intelligence Scale-Revised (DSS/WAIS-R),
and the Word Fluency (WF) Test) using data from the first follow-up visit of the cohort (1990-1992). No
consistent associations were seen between ERT and either the DWR test or the DSS/WAIS-R after adjusting
for age, education, and additional covariates previously found to be associated with cognitive function scores.
Among surgically menopausal women aged 48-57 years, adjusted mean WF scores were slightly greater in
ERT current users (mean WF 35.9) than in never users (mean WF 33.5) (p < 0.02); and within current users,
adjusted WF scores increased with duration of ERT use. However, the finding that ERT was associated with
a slightly higher level of performance on only one of three measures offers little support for the hypothesis that
ERT has a major protective effect on cognitive function in women less than 68 years of age. The generalizability
of these findings to older women who are more likely to experience cognitive decline and who may be using
ERT for longer periods of time is limited by the relatively young age of the cohort. Am J Epidemiol 1996;144:
1048-57.
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Age-related loss in cognitive function is likely to be
the result of complex relations between biologic and
environmental factors, involving multiple risk factors
and mechanisms (1-5). It has been suggested, how-
ever, that an important mechanism may be a deficit in
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central cholinergic transmitter activity (2, 6-10). Es-
trogens are known to affect the synthesis of acetylcho-
line through an increase in the activity of choline
acetyltransferase (8). Estrogen may also be important
in maintaining neuronal interconnections in localized
areas of the brain such as the basal forebrain, hip-
pocampus, and cerebral cortex, which are all important
areas for cognitive functioning (11-13).
Assessment of the relation of estrogen replacement
therapy (ERT) to cognitive functioning in humans has
been based on studies of small samples (14-17) or
studies of older women (18), including those with
Alzheimer's disease (19, 20). Unlike research evalu-
ating the benefits of estrogens on clinical cardiovas-
cular outcomes (21), these studies have yielded incon-
sistent results (16, 18-20). Thus, there is a need to
continue to examine the relation of ERT to cognitive
functioning in large samples of women. Data from the
Atherosclerosis Risk in Communities (ARIC) study,
on which the present analyses were based, offered an
opportunity to examine the hypothesis of a protective
effect of ERT on cognitive test performance in a large
crosssectional sample of women, many of whom had
become postmenopausal relatively recently.
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MATERIALS AND METHODS
Study population
The ARIC study is a prospective investigation of
clinical and subclinical atherosclerosis in four US
communities: Forsyth County, North Carolina; Jack-
son, Mississippi; selected Minneapolis suburbs, Min-
nesota; and Washington County, Maryland. The study
included population samples totaling 15,792 individ-
uals aged 45-64 years at the time of the baseline
examination of which 8,685 (55 percent) were women.
About 14 percent in Forsyth County were African-
American. Participants in Jackson were exclusively
African-American. The Minneapolis and Washington
County cohorts were predominantly white. An over-
view of the study design and procedures has been
published (22).
A baseline examination of the total cohort was car-
ried out in 1987-1989 (visit 1) and a follow-up exam-
ination, 3 years later, in 1990-1992 (visit 2) when the
cohort was aged 48-67 years. Of the 8,481 African-
American and white women who were alive at the
time of the first follow-up visit (visit 2), 7,921 (93.4
percent) completed this visit, which included cognitive
function tests. Women were excluded from our anal-
yses if information was missing on any of the cogni-
tive test scores {n = 84), if they had primary amen-
orrhea or their menopausal status could not be
precisely determined (n = 821), or if they were post-
menopausal women who lacked information on cur-
rent or past use of ERT (n = 238). Women with a
history of stroke or transient ischemic attacks (n =
465) or those taking antipsychotic medications (n =
197) were also excluded. In addition, six women with
missing information on education were excluded. The
final study population on which the present analyses
are based was comprised of 6,110 women.
Study variables
For the present report, data on menopausal status,
use of ERT, and cognitive scores were obtained in the
first follow-up visit (visit 2). Information on educa-
tion, self-reported health status, fibrinogen, and sport
index was available only for the baseline visit (visit 1).
All other variables are based on visit 2.
Three neuropsychological tests were applied to the
cohort in the follow-up visit: the Delayed Word Recall
(DWR) Test (23), the Digit Symbol Subtest of the
Wechsler Adult Intelligence Scale-Revised (DSS/
WAIS-R) (24), and the Word Fluency (WF) (or Con-
trolled Oral Word Association) Test (25) of the Mul-
tilingual Aphasia Examination (26). The tests were
administered in study clinics located in each commu-
nity during one session in a quiet room. The DWR and
WF tests were administered by trained interviewers.
The DSS/WAIS-R test is self-administered after stan-
dardized instruction and is a timed test
Interviewer performance in ARIC is monitored by
tape recording and reviewing by the study coordinator
of a random sample of taped interviews. No systematic
departures from the protocol were detected by listen-
ing to the tapes. In addition, mean scores of these
neuropsychological tests obtained by different inter-
viewers were found to be similar.
The DWR test is a test of verbal learning and recent
memory. It requires the respondent to recall 10 com-
mon nouns after a 5-minute interval during which
another test is given. To standardize the elaborative
processing of the words to be recalled, individuals are
required to compose sentences incorporating the nouns
as presented. Test scores range from zero to 10 words
recalled. This test has been shown to have a high
6-month test-retest reliability in a study including 26
normal elderly persons (Pearson's correlation coeffi-
cient (r) = 0.75) (23).
The DSS/WAIS-R is a paper and pencil test requir-
ing timed translation of numbers 1-9 to symbols using
a key. The test measures psychomotor performance
and is relatively unaffected by intellectual ability,
memory, or learning for most adults (24). It appears to
be a sensitive and reliable marker of brain damage
(26). The Digit Symbol Subtest was scored as the
number of numbers correctly translated to symbols
within 90 seconds; the maximum possible is 93. Short-
term test-retest reliability has been found to be high in
middle-aged individuals (r = 0.82) (24).
The WF test requires the participant to generate as
many words as possible in 60 seconds beginning with
a letter from the alphabet. Three trials using the letters
F, A, and S were conducted, and the WF score was the
total number of words generated over the three trials.
The test is particularly sensitive to linguistic impair-
ment (25, 27) and early mental decline in older per-
sons (28). It is also a sensitive indicator of damage to
the left lateral frontal lobe (25, 27). The immediate
test-retest correlation coefficient based on an alternate
test form has been found to be 0.82 (29).
Answers to questions on menopause and current use
of ERT were ascertained by a trained interviewer.
Premenopausal women were those who reported hav-
ing menstruated in the 2 years before the ARIC ex-
amination and who labeled themselves as premeno-
pausal. Women who reported that they had
menstruated in the 2 years before the examination but
who labeled themselves as postmenopausal or as un-
certain menopausal status were categorized as peri-
menopausal. Postmenopausal women were those who
had not menstruated in the last 2 years. Postmeno-
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pausal women were further classified into two groups
according to type of menopause: surgical menopause,
if they had had a bilateral oophorectomy, or natural
menopause. The natural menopause group also in-
cluded nonmenstruating women 55 years of age or
older who had had a hysterectomy and had at least one
intact ovary. The menopausal status of women less
than 55 years of age who had had a hysterectomy
without bilateral oophorectomy could not be deter-
mined, and they were not included in the final study
sample. Postmenopausal women were subclassified as
current users (alone or in combination with progestin),
former users, and never users of ERT.
ERT included the use of estrogen or estrogen and
progestin preparations. Current users included 938 us-
ers of estrogen alone, of whom 84 percent took con-
jugated estrogens, and 246 were users of estrogen and
progestin preparations. Of the latter group, 83 percent
were users of conjugated estrogens plus medroxypro-
gesterone acetate. Former users included 588 past us-
ers of estrogen and 131 past users of estrogen and
progestin preparations.
Information on education was self-reported by study
participants. Diastolic and systolic blood pressure lev-
els were calculated as the average of the second and
third of three consecutive measurements with a ran-
dom zero sphygmomanometer. Hypertensives were
individuals who had systolic blood pressure of 2:140
mmHg, or diastolic blood pressure of 5:90 mmHg, or
were taking antihypertensive medication. Women
were classified as diabetic if they self-reported diabe-
tes, were taking medication for diabetes, had a fasting
plasma glucose level >140 mg/100 ml, or had a non-
fasting glucose level 5:200 mg/100 ml. Standardized
interviews were conducted to determine self-reported
physician-diagnosed history of stroke or transient isch-
emic attack. Physical activity during sport was as-
sessed using a modified version of the Baecke et al.
Questionnaire (30) and summarized in a sport index. A
depression symptoms score (0-26 range from low to
high) was defined using 13 depression-related items
from the Maastricht Questionnaire (31). Body mass
index was calculated as weight(kg)/height(m2).
Plasma fibrinogen was assessed as previously de-
scribed (22). Marital status, self-reported health status,
and history of smoking and alcohol intake were ascer-
tained by means of interviews.
Statistical analyses
Unadjusted mean and percentile values of cognitive
test scores were examined in relation to menopausal
status and use of ERT. The distribution of potential
confounders by use of ERT in menopausal women was
examined by comparing means and proportions across
groups.
Adjustment for selected variables was carried out
using linear regression methods. Selection of potential
confounding variables was based on examination of
associations with ERT and cognitive function. Mean
scores were adjusted for age, race, education, marital
status, self-reported health status, depression score,
smoking status, drinking status, hypertension, diabe-
tes, plasma fibrinogen, body mass index, and sport
index. Among postmenopausal women, scores were
also adjusted for time since menopause. Age, depres-
sion score, fibrinogen, sport index, body mass index,
and time since menopause were included as continu-
ous variables. All other variables were included as
dummy variables. Education was categorized as fol-
lows: 8th grade or less, 9-1 lth grade, high school
completion, vocational school, incomplete college,
college completion, and graduate or professional
school. Self-reported health status was based on four
categories: excellent, good, fair, and poor. Smoking
and drinking status was categorized as current, former,
and never. Marital status was categorized as married,
widowed, separated/divorced, and never married.
The adjusted analyses of mean scores were done for
two age strata in years: 48-57, which included pre-,
peri-, and postmenopausal women; and 58-67, in-
cluding only postmenopausal women (these age
groups correspond approximately to the age groups
45-54 and 55-64 at visit 1 commonly used in reports
of AR1C baseline findings). To explore the relation
between duration of ERT use and cognitive scores,
current and former users of ERT were categorized into
three groups based on the tertiles of the distribution of
the duration of use of estrogens. Adjusted mean dif-
ferences for each duration of use category with respect
to never users were estimated for current and former
users separately.
RESULTS
A total of 6,110 women were available for analysis,
of whom 4,549 were white (74.5 percent). As seen in
table 1, the mean age of these women was about 57
years at visit 2, when the cognitive tests were con-
ducted. Thirty-four percent had at least some college
education.
At the time of the first follow-up visit, 78.0 percent
of the study participants were postmenopausal. Bilat-
eral oophorectomy (surgical menopause) had occurred
in 17.8 percent of all women and accounted for nearly
one fourth of the postmenopausal women. As ex-
pected, the proportion of ERT use, particularly current
use, was appreciably greater in surgically menopausal
than in naturally menopausal women (table 2). Mean
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TABLE 1. Characteristic* of 6,110 women in the study
sample, the Atherosclerosis Risk In Communities Study
Characteristic Mean(SD*)
Age at visit 2
Education
Incomplete high school
Complete high school or
vocational school
College or more



















* SD, standard deviation; DWR, Delayed Word Recall Test;
DSS/WAIS-R, Digit Symbol Subtest of the Wechsler Adult
Intelligence Scale-Revised; WF, Word Fluency Test.
cognitive scores for the total study population were
6.9, 47.0, and 34.1 for the DWR, DSS/WAIS-R, and
the WF tests, respectively. The coefficients of varia-
tion for these tests were, respectively, 22, 31, and 36
percent, indicating reasonable variability around the
mean values.
In general, current users tended to have used hor-
mones longer than former users, and older women had
used hormones longer than younger women (data not
shown in a table). Among women aged 48-57 years,
the median duration of estrogen use was 6 years (in-
terquartile range 3-10) among current users and 1 year
(interquartile range 0 -4 years) among former users.
Among women aged 58-67, the median duration of
use was 9 years among current users (interquartile
range 3-16 years) and 2 years among former users
(interquartile range 0-6).
Mean scores for all three tests were inversely related
to age and directly related to educational level (not
shown in a table). For example, for those with a
college education, mean score differences between
younger (48- to 57-year-old) and older (58- to 67-year-
old) women were 0.5 for the DWR test, 5.6 for the
DSS/WAIS-R, and 1.8 for the WF test. In younger
subjects, the differences between those with a graduate
education and those with incomplete high school were
0.9 for the DWR test, 19.4 for the DSS/WAIS-R, and
18.1 for the WF test.
The distributions of potential confounding variables
by ERT use in postmenopausal women are shown in
table 3. Current ERT users were younger, better edu-
cated, more likely to be white, and more often married
than never users. Current users were also more likely
TABLE 2. Percentages of ERT* use by type of menopause
for 6,110 women in the study sample, the Atherosclerosis
Risk In Communities Study















* ERT, use of estrogen or estrogen + progestin.
than never users to perceive themselves in excellent or
good health, were less frequently hypertensive or di-
abetic, had a lower body mass index, were less often
smokers but more often drinkers, and had lower mean
depression scores and a lower mean fibrinogen level.
Mean values for the sport index were similar in cur-
rent, former, and never users of ERT. With the excep-
tion of depression score and sport index, former users
occupied an intermediate position between never and
current users in risk factor profiles. Mean age at meno-
pause decreased slightly from never, to former, to
current users. Time since menopause was slightly
greater in women who reported being former users
than in the other two groups.
The unadjusted means of cognitive test scores by
menopausal status and use of ERT are not meaningful
because they are likely to be heavily confounded by
age and education. Thus, for all tests, mean scores
were found to be lower for post- than for premeno-
pausal women; among the postmenopausal, they were
lower for ERT never users than for current users, with
former ERT users showing intermediate values (data
not shown in a table). For example, for the WF test,
the mean scores were 37.2 for premenopausal and 33.2
for postmenopausal women. For the natural meno-
pausal group, the mean WF test scores were 32.5 for
never users of ERT, 34.6 for former users, and 35.9 for
current users; for the surgical menopausal group, they
were 28.9, 33.1, and 34.9, respectively. A similar pat-
tern was found for the DWR test and the DSS/WAIS-R
Examination of multivariable-adjusted mean cogni-
tive scores in pre-, peri-, and postmenopausal women
was limited to ages 48-57. For ages 58-67, only
postmenopausal women were included. The age dis-
tributions were fairly homogenous across the age
range in both age categories.
Among women aged 48-57 years (table 4), mean
WF test scores were slightly higher for ERT former
and current users than for never users in both naturally
and surgically menopausal women. These differences
Am J Epidemiol Vol. 144, No. 11, 1996
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TABLE 3. Distribution of potential confound*™ by i












































































• SE, standard error,
t As defined In text
were statistically significant at the alpha = 0.05 level
for current users only among surgically menopausal
women. Patterns for the other cognitive scores were
inconsistent and not supportive of the hypothesis of a
protective effect of ERT.
For 58- to 67-year-old women (table 3), former and
current users had slightly higher mean WF test scores
than never users among both naturally and surgically
menopausal women, but differences were not statisti-
cally significant at the alpha = 0.05 level. No consis-
tent patterns were observed for the other cognitive
scores.
In both age groups, the patterns observed in post-
menopausal women remained similar after additional
adjustment for time since menopause.
The analyses above were repeated using the odds of
having a cognitive score at or below the 20th percen-
tile relative to having a score equal to or above the
median value as the outcome. Results (not shown)
were generally similar to those obtained using cogni-
tive scores as continuous variables.
Mean differences in cognitive scores by duration of
ERT use in current users are shown in table 5. In
postmenopausal women aged 48-57, mean WF test
scores increased slightly with increasing duration of
ERT use in both naturally and surgically menopausal
women.
Using linear regression, this trend was statistically
significant when entering the median values for each
tertile (/? = 0.004) in surgically menopausal women.
No consistent or statistically significant patterns were
observed for the other cognitive scores.
In postmenopausal women aged 58-67 years, mean
WF test scores increased slightly in current users who
were in the two upper duration of use categories, as
compared with never users; however, differences were
not statistically significant at the 0.05 level (table 5).
Findings for the lowest third of duration of ERT use
were not consistent with a protective effect of ERT.
No clear patterns were documented for the other cog-
nitive scores. Among former users, no clear associa-
tions were observed between duration of ERT use and
cognitive scores (data not shown).
Because improvement of depressive mood has been
postulated as an explanation for the possible link be-
tween ERT and cognitive functioning (14, 18, 32-36),
adjusted means were recalculated after removing de-
pression score from the linear regression function;
however, results remained virtually unchanged.
Analyses replacing ERT and menopause data ob-
tained in the follow-up visit conducted in 1990-1992
with data collected during the baseline visit (1987-
1989) yielded very similar results (data not shown).
DISCUSSION
Current therapies aimed at improving cognitive
functioning are based on correcting the deficit in cen-
tral cholinergic transmitter activity that may explain
the age changes in cognitive performance (7, 8). For
example, administration of estradiol to oophorecto-
mized female rats is associated with an increased
activity of choline acetyltransferase in the brain (8, 9).
Estrogen may also be important in maintaining neuro-
nal interconnections. Growth-promoting effects of es-
Am J Epidemiol Vol. 144, No. 11, 1996
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TABLE 4. Adjusted mean cognitive scores and standard errors (SEs) by menopausal status and use of
estrogen replacement therapy (ERT) stratified by age, the Atherosclerosis Risk In Communities S t u d y t 4
Premenopausal (n = 692)
Perimenopausal (n = 564)
Natural menopause
ERT never (n •» 878)
ERT former (n •= 150)
ERT current (n = 316)
Surgical menopause
ERT never (n = 139)
ERT former (n =117 )






















Postmenopausal women aged 58-67years (n = 2,694)
Natural menopause
ERT never (n= 1,607)
ERT former (n - 3 1 5 )
ERT current (n = 331)
Surgical menopause
ERT never (n= 159)
ERT former (n =121 )





























* p value for difference vls-a-vis never users In each group < 0.05.
t Adjusted for age, race, education, marital status, self-reported health status, depression score, smoking
status, drinking status, hypertension, diabetes, serum fibrinogen, body mass index, and sport index, as defined in
text All scores rounded to nearest tenth.
$ O f the 6,110 women in the study population, 52 were excluded from this table because they were 58 years
of age or over but were not postmenopausal. An additional 156 women were excluded because they had missing
information on one or more of the covariates.
§ DWR, Delayed Word Recall Test; DSSAVAIS-R, Digit Symbol Subtest of the Wechsler Adult Intelligence
Scale-Revised; WF, Word Fluency Test
trogen on neurons have been demonstrated in organo-
typic explant cultures of adult rat CNS (37, 38) and in
studies of bilateral ovariectomized rats (39). The latter
studies have shown a significant decrease in apical
dendritic spine density in the CA1 pyramidal cells of
the hippocampus of ovariectomized rats, which can be
blocked with the administration of estrogen. Further-
more, estrogen may make neurons of the basal fore-
brain (12), as well as the hippocampus and cerebral
cortex (13), more sensitive to neurotrophins (e.g.,
nerve growth factor); neurotrophins have an important
role in the growth and maintenance of dendrites and
axons. In addition, it has also been hypothesized that
in humans, ERT could indirectly affect cognitive func-
tioning through an improvement of the depressive
mood that seems to occur with menopause (14, 18,
32-36).
Broad cognitive domains including psychomotor
speed and efficiency, language, and memory are sam-
pled by the three neuropsychological instruments used
in the present study, which have been shown to be
sensitive to brain dysfunction. The WF test—for
which the only somewhat consistent associations were
documented—is sensitive to linguistic impairment and
has been used in a dementia screening battery (40) and
to detect early mental decline in older persons (27, 28).
The WF test is also sensitive to frontal lobe dysfunc-
tion, particularly that of the left frontal lobe (41).
However, the WF test is not specific for frontal lobe
dysfunction, and scores can be influenced by damage
to a variety of areas of the brain (27). Thus, no
conclusions can be drawn from lower performance on
the WF test and decreased function of a specific area
of the brain. However, the difference in effects of WF
compared with DSSAVAIS-R scores could be consis-
tent with prior claims that the effects of estrogen are
more potent on verbal processes (18, 42). Perhaps the
effect on verbal performance is at the level of retrieval
rather than encoding, to account for the lack of effect
on the DWR results.
The current study, the largest to date, provides weak
(if any) support for the hypothesis that ERT is inde-
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TABLE 5. Adjusted mean differences and standard errors (SEs) In cognitive scores by duration of use






Postmenopausal woman aged 48-57 years




Lowest third (0-3 years)
Middle third (4-8 years)
Upper third (9-44 years)
Surgical menopause (n = 480)
ERT never users
Lowest third (0-3 years)
Middle third (4-8 years)

















Postmenopausal women aged 58-67 years
Natural menopause (n = 1,874)
ERT never users
Lowest third (0-5 years)
Middle third (6-13 years)
Upper third (14-46 years)
Surgical menopause (n = 318)
ERT never users
Lowest third (0-5 years)
Middle third (6-13 years)

































* p value for linear trend using median values for each fertile 0.004.
t Adjusted for age, race, education, time since menopause, marital status, self-reported health status,
depression score, smoking status, drinking status, hypertension, diabetes, serum flbrlnogen, body mass Index,
and sport Index, as defined In text All scores rounded to nearest tenth. TeiHles based on distribution of duration
of use In each age group.
t DWR, Delayed Word Recall Test; DSSAVAJS-R, Digit Symbol Subtest of the Wechsler Adult Intelligence
Scale-Revised; WF, Word Fluency Test
pendently related to cognitive functioning in post-
menopausal women less than 67 years of age. Consis-
tent associations were documented for only one of the
tests—the WF test—and were statistically significant
only in surgically menopausal women 48-57 years of
age. Although a stronger ERT effect in surgically than
in naturally menopausal women is consistent with the
hypothesis of a protective effect of ERT, the fact that
patterns were clearer in younger than in older women
is not consistent, inasmuch as one would expect the
ERT effect to be stronger in older women who are
more likely to be affected by cognitive decline.
Chance is a possible explanation for our findings. We
performed a total of 24 comparisons: Former and
current ERT users were compared with never users in
two categories of menopause (natural and surgical)
and two age groups (48-57 and 58-67 years) using
three cognitive tests (see table 4). Of these compari-
sons, only one (4 percent) was statistically significant.
In addition, even when associations were documented,
they tended to be relatively weak. For example, in the
younger (48- to 57-year-old) surgically menopausal
women, in whom the association with mean WF score
was strongest, the difference between current and
never users—although statistically significant—trans-
lates into an average of only 2.4 words generated per
minute (table 4). In postmenopausal women 48-57
years old, increasing duration of use of ERT did ap-
pear to be associated with increasing WF scores. How-
ever, because of the high correlation of word fluency
with education, the WF test scores may be an addi-
tional independent proxy for intellect. Thus, any mis-
classification or residual confounding by education
and the lack of a direct measure of intellect could
explain the associations observed both for current
versus never users and for duration of use. Further-
more, it could be postulated that if ERT exerts a
protective effect on word fluency but not recall, then
its protective effect is probably not on some type of
pre-Alzheimer's process.
Previous studies examining the association of ERT
with cognitive function in individuals both with and
Am J Epidemiol Vol. 144, No. 11, 1996
Estrogen Replacement Therapy and Cognitive Function 1055
without Alzheimer's disease have yielded inconsistent
results. In small studies, results have either favored
(14) or not favored (15, 17) the hypothesis that ERT
protects against menopause-related decline in cogni-
tion.
Sherwin (16) conducted a crossover randomized
clinical trial including 50 women undergoing surgical
menopause who were given a combined estrogen-
androgen preparation, estrogen alone, or androgen
alone. She found no differences in cognitive test re-
sults between the postoperative treatment and the pre-
operative phases. However, presumably because
women who had a hysterectomy but whose ovaries
were not removed showed stability in both cognitive
performance and circulating sex steroid concentra-
tions, the author concluded that changes in the endo-
crine milieu after bilateral oophorectomy may have an
effect, albeit modest, on cognitive functioning.
In a subsequent study of 19 women undergoing
hysterectomy with bilateral oophorectomy for benign
disease, Phillips and Sherwin (42) randomly assigned
10 women to receive estrogen and nine women to
receive placebo after surgery; the Wechsler Memory
Scale was given preoperatively and again 2 months
postoperatively. The results suggested that estrogen
influenced verbal memory (as measured by immediate
and delayed recall of paired associates and immediate
recall of paragraphs), but not visual memory (as mea-
sured by immediate or delayed recall from the Visual
Reproduction Test) or attention (as measured by digit
span).
An observational prospective study of the associa-
tions of ERT with results of 12 cognitive tests was
conducted by Barrett-Connor and Kritz-Silverstein
(18) in 800 elderly women (mean age 77 years) living
in Rancho Bernardo, California. The authors found
that current or past use of ERT was largely unrelated
to cognitive scores, but women who used estrogen for
at least 20 years scored significantly higher on the
category fluency test (a test very similar to word
fluency) compared with never users.
Recent case-control studies of the relation of ERT to
cognitive functioning have focused on patients with
Alzheimer's disease. Paganini-Hill and Henderson
(20) carried out a nested case-control study within the
Leisure World Cohort study. They identified 138 de-
ceased individuals whose death certificates mentioned
Alzheimer's disease, senile dementia, dementia, or
senility from a total of approximately 2,500 deaths
occurring in the cohort from 1981 through 1992. Four
death- and birthdate-matched deceased controls were
chosen for each case. The odds of "caseness" was
found to be lower in ERT users than in nonusers (odds
ratio = 0.69, 95 percent confidence interval 0.46-
1.03). Although this study provided evidence that ERT
may have an effect on postmenopausal Alzheimer's
and related diseases, the inclusion of only dead cases
and controls makes it difficult to discern the effect on
incidence from that on case fatality.
Brenner et al. (19) identified 107 cases of newly
diagnosed Alzheimer's disease and 120 age-matched
controls among female members of the Group Health
Cooperative of Puget Sound, Seattle, Washington. The
authors could not find an association with ERT after
adjusting for age and hysterectomy before or after age
55 (odds ratio for users/nonusers = 1.1, 95 percent
confidence interval 0.6-1.8).
Our results should be interpreted with caution, in
view of the limitations of the study. First, our findings
are cross-sectional, raising concerns about possible
selection bias. If women who are having memory
problems are more likely to be prescribed ERT by
their physicians, our failure to detect associations may
be due to the selection of women with low cognitive
scores into the ERT current users group. On the other
hand, because survival may be better both in individ-
uals who perform well in cognitive testing (43-46)
and in those using ERT (21), persons using ERT and
with preserved cognitive functioning may be more
likely to be alive and willing to participate in the ARIC
study. This type of bias, however, would lead to an
overestimation of the associations supporting the hy-
pothesis of a protective effect. Thus, although possibly
explaining some of the WF test results, survival bias
is an unlikely explanation for our failure to detect
consistent associations with the DWR test and the
DSS/WAIS-R results.
Another potential problem in the study is that recall
bias regarding use of ERT may be more severe in
persons scoring lower on cognitive tests. Furthermore,
although we attempted to control for multiple con-
founding variables, our study also suggests that ERT
current users and never users differ in a variety of
ways, raising the possibility of residual confounding.
One major caveat regarding the degree to which the
data in this paper argue against the protective effect of
ERT on cognitive function is the relatively young ages
of the study participants. The duration of use among
ERT users may have been too short for it to have a
detectable effect on cognitive function. If the protec-
tive effects of ERT appear only with increasing dura-
tion of use and increasing time after menopause, they
may not yet be apparent in most of our cohort mem-
bers. In addition, the study population may be too
young to experience substantial cognitive decline,
making it virtually impossible to detect a protective
effect of ERT, even if it in fact exists. The fact that the
only statistically significant associations we observed
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were in younger rather than older women (contrary to
what one would expect) further argues for the possi-
bility that these associations are due to residual con-
founding rather than to a true effect of ERT in these
age groups.
The finding that ERT was not clearly associated
with a higher level of performance may on the one
hand reflect the fact that a major protective effect on
cognitive functioning is seen only in older women. On
the other hand, it is possible that the WF test—for
which a slightly better cognitive performance was
seen—is more sensitive to early cognitive decline than
the DWR test in the pre-Alzheimer's process. With
additional cohort follow-up, the ARIC investigators
will be able to revisit the hypothesis that ERT has a
protective effect on cognitive decline using prospec-
tive data on an aging cohort. Additional follow-up will
allow assessment not only of cognitive functioning at
a given visit but also of temporal changes.
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